MammaPrint - 70-gene test - MINDACT trial publication

Options
BarredOwl
BarredOwl Member Posts: 2,433
edited August 2016 in Clinical Trials, Research News, Podcasts, and Study Results

Following an abstract and presentation at AACR in April 2016, a full-length paper with results from the MINDACT trial of the MammaPrint (70-gene) test has now been published here:

2016, NEJM "preview": http://www.nejm.org/doi/full/10.1056/NEJMoa1602253

(A complete pdf copy of the above article is available with subscripton or for one-time fee)

Perspective (starts part way down the page): http://www.nejm.org/doi/pdf/10.1056/NEJMp1608282

Related editorial: http://www.nejm.org/doi/pdf/10.1056/NEJMe1607947

BarredOwl

· Share on FacebookShare on Twitter

Comments

  • wallycat
    wallycat Member Posts: 3,227
    edited August 2016

    I just read the NEJM link but did not see what they use as a "cut off" number similar to oncotypedx.....but it looks promising the low-intermediates may do just fine without chemo.


    And as an aside, I JUST saw my first Barred owl yesterday on a hike. I think it was an older "chick" that just sat on a branch and watched DH and I. GORGEOUS. Such a face! This was at 10am and just shocked to have stumbled on it!!

    · Share on FacebookShare on Twitter
  • BarredOwl
    BarredOwl Member Posts: 2,433
    edited August 2016

    Hi wallycat:

    The MammaPrint test has a "binary" output: either "high risk" or "low risk". The test measures mRNA expression levels from 70 genes. A computer program assembles an expression profile from the data, and calculates a MammaPrint Index ("MPI") value between -1.0 and +1.0. Negative values (below the "clinical classification threshold" of zero) fall into the "high risk" category, while positive values (above zero) fall into the "low risk" category.

    Neat you saw one of my relatives.

    BarredOwl

    · Share on FacebookShare on Twitter
  • ChiSandy
    ChiSandy Member Posts: 12,133
    edited August 2016

    Slightly off-topic, but I subscribe to GenomeWeb’s e-mail bulletins (several times a day), and invariably anything pertinent about breast cancer requires a “premium” subscription. Not forking over a C-note per year. Any way around this?

    · Share on FacebookShare on Twitter
  • BarredOwl
    BarredOwl Member Posts: 2,433
    edited August 2016

    We now have layperson summaries of the MINDACT study results and editorial:

    MedScape: http://www.medscape.com/viewarticle/867988#vp_1

    Registration is free, but you can access the full text without registration by googling the title of the article:

    "MammaPrint Finds Breast Cancer Patients Who Can Skip Chemo"

    And, thanks for cp418 for the link to this STAT article in another thread:

    STAT: https://www.statnews.com/2016/08/24/breast-cancer-dna-medical-tests/

    BarredOwl

    · Share on FacebookShare on Twitter

Categories